NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

NCT03547700 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

NCT05014412 ·Status: COMPLETED ·Phase: PHASE2

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

NCT05576532 ·Status: UNKNOWN ·Phase: PHASE2

Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

NCT03770416 ·Status: COMPLETED ·Phase: PHASE2

Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

NCT03127020 ·Status: COMPLETED ·Phase: PHASE2

Nivolumab/Ipilimumab in Second Line CUP-syndrome

NCT04131621 ·Status: UNKNOWN ·Phase: PHASE2

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT03075553 ·Status: TERMINATED ·Phase: PHASE2

Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma

NCT01939899 ·Status: COMPLETED ·Phase: PHASE2

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

NCT04231370 ·Status: UNKNOWN ·Phase: PHASE2

Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

NCT01947140 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

NCT02341014 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

NCT00003245 ·Status: COMPLETED ·Phase: PHASE2

MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma

NCT00059995 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01096342 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

NCT01822886 ·Status: COMPLETED ·Phase: PHASE2

Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma

NCT05427812 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Tocladesine in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT00004902 ·Status: COMPLETED ·Phase: PHASE2

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

NCT02519270 ·Status: TERMINATED ·Phase: PHASE1

A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma

NCT05446688 ·Status: UNKNOWN ·Phase: PHASE2

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

NCT00086125 ·Status: COMPLETED ·Phase: PHASE2

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

NCT07077512 ·Status: RECRUITING ·Phase: PHASE2

Study of XL999 in Patients With Multiple Myeloma

NCT00304590 ·Status: TERMINATED ·Phase: PHASE2

Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

NCT03119467 ·Status: TERMINATED ·Phase: PHASE1

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

NCT00060645 ·Status: COMPLETED ·Phase: PHASE1

Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

NCT05673967 ·Status: COMPLETED